Article Text

Download PDFPDF

Time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002%: a pilot, comparative study versus ripasudil 0.4%
  1. Etsuko Terao1,
  2. Shunsuke Nakakura1,
  3. Yasuko Fujisawa1,
  4. Yuki Nagata1,
  5. Kanae Ueda1,
  6. Yui Kobayashi1,
  7. Satomi Oogi1,
  8. Saki Dote1,
  9. Miku Shiraishi1,
  10. Hitoshi Tabuchi1,
  11. Tsuyoshi Yoneda2,
  12. Atsuki Fukushima3,
  13. Ryo Asaoka4,
  14. Yoshiaki Kiuchi5
  1. 1Department of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Japan
  2. 2Department of Sensory Science, Kawasaki University of Medical Welfare, Kurashiki, Japan
  3. 3Department of Ophthalmology, Kochi Medical School, Kochi University, Nankoku, Japan
  4. 4Department of Ophthalmology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
  5. 5Department of Ophthalmology, Hiroshima University, Hiroshima, Japan
  1. Correspondence to Dr Shunsuke Nakakura; shunsukenakakura{at}yahoo.co.jp

Abstract

Objective We investigated the detailed time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002% (omidenepag), a selective prostaglandin E2 receptor 2 agonist.

Methods and analysis We recruited 34 healthy subjects and administered omidenepag in the right eye and ripasudil 0.4% in the left eye. We evaluated conjunctival hyperemia using slit-lamp photography at baseline and after 15, 30, 60, 120, 180 and 360 min. The conjunctival hyperemia score was graded by three independent observers using a scale from 0 (none) to 3 (severe). We also evaluated conjunctival hyperemia by the pixel coverage of conjunctival blood vessels (per cent coverage) determined using a conjunctival hyperemia-analysing software.

Results In omidenepag, the conjunctival hyperemia score and per cent coverage peaked at both 30 min (mean score±SD: 1.57±0.67 and 11.90%±3.66%, respectively) and then gradually decreased at 60 min (10.79%±3.32%) and 120 min (1.10±0.52) when they reached a level that was not significantly different from the baseline values. For ripasudil 0.4%, the peak time of the conjunctival hyperemia score and per cent coverage were both at 15 min (score: 2.42±0.54 and 15.26%±3.38%). The degree of conjunctival hyperemia was significantly higher for ripasudil 0.4% than that for omidenepag from 15 to 30 min in both the conjunctival hyperemia score and per cent coverage (p<0.007 by Bonferroni correction).

Conclusion Conjunctival hyperemia induced by omidenepag gradually peaks to moderate severity, though weaker compared with that induced by ripasudil 0.4%, and subsides relatively quickly.

  • glaucoma
  • drugs
  • conjunctiva
  • ocular surface
  • pharmacology
http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Presented at The article has been presented at the 30th Annual Meeting of the Japanese Glaucoma Society on 7 September 2019.

  • Contributors SN had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: SN, YK, AF. Acquisition, analysis or interpretation of data: All authors. Drafting of the manuscript: All authors. Critical revision of the manuscript for important intellectual content: YK, AF. Study supervision: SN, YK, AF, RA.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Ethics approval This study received approval from the Institutional Review Board of Saneikai Tsukazaki Hospital (Himeji, Japan).

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement Data are available in a public, open access repository.